Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) follicular lymphoma, previously untreated follicular...

Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology,...

BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China,...

- 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute leukemia patients treated at RP2D - - 9 of 12 patients who underwent stem...

Exploratory analysis from Cohort 3 of the Phase 2 REFINE study presented in an oral session at ASH NORTH CHICAGO, Ill., Dec. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data...

Updated data presented at ASH include CAPTIVATE and GLOW studies and real-world evidence abstracts NORTH CHICAGO, Ill., Dec. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new and...

Long-term data from the pivotal HOPE-B study show a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding 24-month results...

Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that it has been selected by the American Society of Hematology (ASH) for a poster presentation on its Phase...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its breast cancer radiation signature, Profile...